Insider Buy/Sell Details for the Biotechnology Industry — April 2026
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (1153)
UNITED THERAPEUTICS Corp (UTHR)
EDGEMOND JAMES — CFO AND TREASURER
Shares
2,405
Price
$570.05
Total Value
$1.37M
Shares Held After
21,280
% of Holdings
10.2%
UNITED THERAPEUTICS Corp (UTHR)
EDGEMOND JAMES — CFO AND TREASURER
Shares
1,107
Price
$569.01
Total Value
$629.90K
Shares Held After
23,685
% of Holdings
4.5%
UNITED THERAPEUTICS Corp (UTHR)
EDGEMOND JAMES — CFO AND TREASURER
Shares
919
Price
$567.81
Total Value
$521.82K
Shares Held After
24,792
% of Holdings
3.6%
UNITED THERAPEUTICS Corp (UTHR)
EDGEMOND JAMES — CFO AND TREASURER
Shares
1,449
Price
$566.73
Total Value
$821.19K
Shares Held After
25,711
% of Holdings
5.3%
UNITED THERAPEUTICS Corp (UTHR)
EDGEMOND JAMES — CFO AND TREASURER
Shares
1,716
Price
$565.85
Total Value
$971.00K
Shares Held After
27,160
% of Holdings
5.9%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
36
Price
$164.07
Total Value
$5.91K
Shares Held After
7,666
% of Holdings
0.5%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
409
Price
$163.56
Total Value
$66.89K
Shares Held After
7,702
% of Holdings
5.0%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
231
Price
$162.38
Total Value
$37.51K
Shares Held After
8,111
% of Holdings
2.8%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
280
Price
$161.62
Total Value
$45.25K
Shares Held After
8,342
% of Holdings
3.2%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
44
Price
$160.83
Total Value
$7.08K
Shares Held After
8,622
% of Holdings
0.5%
Insight Molecular Diagnostics Inc. (IMDX)
BROADWOOD PARTNERS, L.P. — 10% Owner
Shares
250,923
Price
$3.64
Total Value
$913.13K
Shares Held After
12,684,884
% of Holdings
2.0%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
35,947
Price
$18.15
Total Value
$652.44K
Shares Held After
1,206,026
% of Holdings
2.9%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
894
Price
$18.15
Total Value
$16.23K
Shares Held After
9,682
% of Holdings
8.5%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
90,943
Price
$18.15
Total Value
$1.65M
Shares Held After
5,058,604
% of Holdings
1.8%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
45,709
Price
$18.15
Total Value
$829.62K
Shares Held After
1,637,302
% of Holdings
2.7%
NovaBridge Biosciences (NBP)
Hagler Mark Arnold — President and Chief Commercial Officer
Shares
230,000
Price
$2.51
Total Value
$577.30K
Shares Held After
230,000
% of Holdings
100.0%
Insight Molecular Diagnostics Inc. (IMDX)
BROADWOOD PARTNERS, L.P. — 10% Owner
Shares
38,880
Price
$3.53
Total Value
$137.08K
Shares Held After
12,433,961
% of Holdings
0.3%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
28,583
Price
$18.48
Total Value
$528.21K
Shares Held After
1,241,973
% of Holdings
2.2%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
710
Price
$18.48
Total Value
$13.12K
Shares Held After
10,576
% of Holdings
6.3%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
72,310
Price
$18.48
Total Value
$1.34M
Shares Held After
5,149,547
% of Holdings
1.4%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
36,345
Price
$18.48
Total Value
$671.66K
Shares Held After
1,683,011
% of Holdings
2.1%
COMPUGEN LTD (CGEN)
Ophir Eran — Director
Shares
5,000
Price
$3.20
Total Value
$16.00K
Shares Held After
11,375
% of Holdings
30.5%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
3
Price
$162.53
Total Value
$487.59
Shares Held After
8,666
% of Holdings
0.0%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
28
Price
$161.22
Total Value
$4.51K
Shares Held After
8,669
% of Holdings
0.3%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
330
Price
$160.40
Total Value
$52.93K
Shares Held After
8,697
% of Holdings
3.7%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
375
Price
$159.46
Total Value
$59.80K
Shares Held After
9,027
% of Holdings
4.0%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
190
Price
$158.65
Total Value
$30.14K
Shares Held After
9,402
% of Holdings
2.0%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
74
Price
$157.86
Total Value
$11.68K
Shares Held After
9,592
% of Holdings
0.8%
COMPUGEN LTD (CGEN)
Levine Zurit — SVP, Business Development
Shares
2,000
Price
$3.20
Total Value
$6.40K
Shares Held After
29,375
% of Holdings
6.4%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
20
Price
$567.41
Total Value
$11.35K
Shares Held After
40,513
% of Holdings
0.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,950
Price
$566.70
Total Value
$1.11M
Shares Held After
40,533
% of Holdings
4.6%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
3,220
Price
$565.36
Total Value
$1.82M
Shares Held After
42,483
% of Holdings
7.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,796
Price
$564.53
Total Value
$1.01M
Shares Held After
45,703
% of Holdings
3.8%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,316
Price
$563.49
Total Value
$741.56K
Shares Held After
47,499
% of Holdings
2.7%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
878
Price
$562.37
Total Value
$493.76K
Shares Held After
48,815
% of Holdings
1.8%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
320
Price
$561.21
Total Value
$179.59K
Shares Held After
49,693
% of Holdings
0.6%
Aditxt, Inc. (ADTX)
HRT FINANCIAL LP — 10% Owner
Shares
29,404
Price
$0.28
Total Value
$8.23K
Shares Held After
88,377
% of Holdings
25.0%
Adaptive Biotechnologies Corp (ADPT)
RUBINSTEIN JULIE — President and COO
Shares
19,060
Price
$14.02
Total Value
$267.22K
Shares Held After
382,132
% of Holdings
4.8%
UNITED THERAPEUTICS Corp (UTHR)
PATUSKY CHRISTOPHER — Director
Shares
2,910
Price
$569.00
Total Value
$1.66M
Shares Held After
1,490
% of Holdings
66.1%
Insight Molecular Diagnostics Inc. (IMDX)
BROADWOOD PARTNERS, L.P. — 10% Owner
Shares
280,381
Price
$3.50
Total Value
$982.03K
Shares Held After
12,395,081
% of Holdings
2.3%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
15,148
Price
$19.19
Total Value
$290.69K
Shares Held After
1,270,556
% of Holdings
1.2%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
377
Price
$19.19
Total Value
$7.23K
Shares Held After
11,286
% of Holdings
3.2%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
38,322
Price
$19.19
Total Value
$735.40K
Shares Held After
5,221,857
% of Holdings
0.7%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
19,261
Price
$19.19
Total Value
$369.62K
Shares Held After
1,719,356
% of Holdings
1.1%
Opus Genetics, Inc. (IRD)
Magrath George — Director
Shares
9,511
Price
$5.22
Total Value
$49.65K
Shares Held After
1,741,344
% of Holdings
0.5%
Opus Genetics, Inc. (IRD)
Jayagopal Ashwath — Chief Scientific & Dev. Ofc.
Shares
7,542
Price
$5.19
Total Value
$39.16K
Shares Held After
509,233
% of Holdings
1.5%
Opus Genetics, Inc. (IRD)
YERXA BENJAMIN R — Director
Shares
7,470
Price
$5.24
Total Value
$39.12K
Shares Held After
711,535
% of Holdings
1.0%
Opus Genetics, Inc. (IRD)
Gagnon Robert E. — Chief Financial Officer
Shares
7,842
Price
$5.18
Total Value
$40.66K
Shares Held After
592,158
% of Holdings
1.3%
Opus Genetics, Inc. (IRD)
SCHACHLE JOSEPH K — Chief Operating Officer
Shares
4,697
Price
$5.22
Total Value
$24.52K
Shares Held After
296,084
% of Holdings
1.6%
Opus Genetics, Inc. (IRD)
Zaremba Rabourn Amy — Head of Fin. Quality Assurance
Shares
1,641
Price
$5.20
Total Value
$8.54K
Shares Held After
188,671
% of Holdings
0.9%
Showing 151–200 of 1153 transactions (page 4 of 24)